Petal Surgical — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Petal Surgical is developing a transformative, non-invasive surgical platform based on Millisecond Pulse Histotripsy, which causes Acoustic Liquefaction of tissue. Founded in 2019 by a team with deep expertise in neurosurgery, robotics, and medical device innovation, the company is backed by notable investors and advisors, including pioneers from Intuitive Surgical. Petal's technology targets the significant global burden of surgical complications and access limitations, positioning it to potentially disrupt multiple therapeutic areas within minimally invasive surgery. The company is currently in a pre-clinical, pre-revenue stage, advancing its platform toward clinical application.

OphthalmologyNeurosurgeryOncology

Technology Platform

Acoustic Sculpting platform using Millisecond Pulse Histotripsy (a form of boiling histotripsy) to perform incisionless tissue liquefaction (Acoustic Liquefaction) via focused sound waves, without heat or cuts.

Opportunities

Petal's incisionless platform addresses a massive unmet need by targeting the 4.2 million annual surgery-related deaths and high complication costs, potentially enabling safer, outpatient-ready procedures.

The multi-indication nature of the core technology allows for expansion beyond initial applications into large markets like oncology, neurology, and cardiology, creating a new paradigm in minimally invasive surgery.

Risk Factors

Key risks include the substantial technical and clinical development challenges of engineering a first-of-its-kind system and proving its safety/efficacy in humans.

The company also faces a difficult regulatory pathway for a novel device and the subsequent hurdle of establishing favorable reimbursement, followed by the commercial challenge of driving surgeon adoption against established surgical paradigms.

Competitive Landscape

Petal is pioneering a new category of incisionless surgery, so it lacks direct competitors using identical technology. However, it will indirectly compete with established players in surgical robotics (e.g., Intuitive Surgical), thermal ablation devices, and other minimally invasive surgical tools. Its long-term competition will likely come from large medtech companies that may develop or acquire similar non-invasive platforms.

More companies in Digital Health & Biotech SaaS →More companies in United States →